isoxazoles has been researched along with hp 873 in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (9.00) | 18.2507 |
| 2000's | 24 (24.00) | 29.6817 |
| 2010's | 55 (55.00) | 24.3611 |
| 2020's | 12 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brecher, MB; Chi, E; Grasing, K; Hubbard, JW; Sainati, SM | 1 |
| Conway, PG; Corbett, R; Cornfeldt, M; Rush, DK; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Mutlib, AE; Strupczewski, JT | 1 |
| Conway, PC; Corbett, R; Dunn, RW; Hartman, H; Helsley, GC; Kerman, LL; Strupczewski, JT; Woods, AT | 1 |
| Bordeau, KJ; Chiang, Y; Conway, PG; Corbett, R; Glamkowski, EJ; Hartman, HB; Helsley, GC; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Chesson, SM; Mutlib, AE; Strupczewski, JT | 1 |
| Brougham, LR; Conway, PG; Ellis, DB; Roehr, JE; Szczepanik, AM; Wilmot, CA | 1 |
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Klein, JT; Mutlib, AE | 1 |
| Jain, KK | 1 |
| Hoyer, D; Kalkman, HO; Subramanian, N | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Kalkman, HO; Subramanian, N | 1 |
| Dai, J; Ichikawa, J; Li, Z; Meltzer, HY | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Enz, A; Gemperle, AY; Lüthi, A; Olpe, HR; Pozza, MF | 1 |
| Feuerbach, D; Kalkman, HO; Lötscher, E; Schoeffter, P | 1 |
| Gemperle, AY; McAllister, KH; Olpe, HR | 1 |
| Barr, AM; Geyer, MA; Markou, A; Powell, SB | 1 |
| Albers, LJ; Musenga, A; Raggi, MA | 1 |
| Lavedan, C; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Potkin, SG | 1 |
| Cutler, AJ; Polymeropoulos, MH; Weiden, PJ; Wolfgang, CD | 1 |
| Cutler, AJ; Hamilton, J; Kalali, AH; Weiden, PJ; Wolfgang, CD | 1 |
| Di Marino, M; Kane, JM; Laska, E; Lauriello, J; Wolfgang, CD | 1 |
| Litman, RE; Potkin, SG; Torres, R; Wolfgang, CD | 1 |
| Hamilton, J; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Thompson, A; Volpi, S; Wolfgang, CD | 1 |
| Hamilton, JB; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Lavedan, C; Licamele, L; Malhotra, AK; Potkin, SG; Volpi, S | 1 |
| Citrome, L | 5 |
| Scott, LJ | 1 |
| Cutler, AJ | 1 |
| Lavedan, C; Thompson, A; Volpi, S | 1 |
| Caccia, S; Nobili, A; Pasina, L | 1 |
| Caballero, J; Marino, J | 1 |
| Janicak, PG; Rado, J | 1 |
| Bishop, DL; Bishop, JR | 1 |
| Richelson, E | 1 |
| Roman, MW | 1 |
| Dopheide, JA | 1 |
| Arif, SA; Mitchell, MM | 1 |
| Howland, RH | 1 |
| Crabtree, BL; Montgomery, J | 1 |
| Citrome, L; Hochfeld, M; Meng, X | 1 |
| Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F | 1 |
| Grant, JS; Keltner, NL; Moore, RL | 1 |
| Bhosale, SH; Dash, RC; Kanhed, AM; Mahadik, KR; Shelke, SM; Suryawanshi, MR | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Weiden, PJ | 1 |
| Drolet, B; Patoine, D; Pilote, S; Simard, C; Vigneault, P | 1 |
| Cvelich, RG; Kincaid, BR; Muzyk, AJ; Preud'homme, XA | 1 |
| Hopkins, CR | 1 |
| Stahl, SM; Tarazi, FI | 1 |
| Correll, CU; De Hert, M; Detraux, J; Sweers, K; van Winkel, R; Yu, W | 1 |
| Bobo, WV | 1 |
| Hochfeld, M; Meng, X; Potkin, SG; Preskorn, S | 1 |
| Cutler, AJ; Kalali, AH; Kunovac, J; Mattingly, GW; Meng, X | 1 |
| Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Wong, D | 1 |
| Freeman, SA | 1 |
| Parekh, JM; Sanyal, M; Shrivastav, PS; Yadav, M | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Fan, Y; He, X; Jia, M; Li, J; Li, W; Liu, M; Zhou, Y | 1 |
| Preskorn, SH | 1 |
| Dargani, NV; Malhotra, AK | 1 |
| Stahl, SM | 1 |
| Mandpe, L; Pokharkar, V | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Blackford, M; Gunkelman, S; Pfeiffer, S | 1 |
| Geerts, H; Potkin, S; Roberts, P; Spiros, A | 1 |
| Mandrioli, R; Mercolini, L; Protti, M | 1 |
| Green, AI; Khokhar, JY | 1 |
| Hartwig, J; Kirschning, A | 1 |
| Ahmed, S; Han, G; Mancione, L; Manning, R; Mayo, MG; Ryan, JM; Weiden, PJ; Wolfgang, CD | 1 |
| Arnold, JG; Bowden, CL; Martinez, M; Prihoda, TJ; Singh, V | 1 |
| Klein-Schwartz, W; Stassinos, G | 1 |
| Ballon, JS; Contreras, I; Freyberg, R; Freyberg, Z; Leibel, RL; Lieberman, JA; Mayer, LE; Pajvani, UB; Rosenbaum, M | 1 |
| Gangu Naidu, C; Madhusudhan Rao, V; Nagesh Kumar, K; Nageswara Rao, R; Padiya, R; Prasada Rao, AV | 1 |
| Beulah, TE; Maheswari, E; Singh, H; Subeesh, V; Swaroop, AM | 1 |
| Bhasin, B; Londhe, VY | 1 |
| Joshi, SV; Kalyankar, GG; Lodha, SR; Patel, EP; Vyas, BA | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Narala, A; Suram, D; Veerabrahma, K | 2 |
| Danek, PJ; Daniel, WA; Wójcikowski, J | 2 |
| Asamoah, AL; Gosal, R; Grossberg, GT; Nair, A; Salem, A | 1 |
| Hewitt, T; Khokhar, JY; Lalonde, J; Perreault, ML; St-Denis, M; Thériault, RK | 1 |
| Danek, PJ; Daniel, WA; Kuban, W | 1 |
| Choi, BH; Choi, JS; Hahn, SJ; Lee, HJ | 1 |
| Chubanov, V; Gudermann, T; Hill, K; Nörenberg, W; Rössig, A; Schaefer, M; Weidenbach, S; Zierler, S | 1 |
| Earle, RR; Gadela, VR | 1 |
30 review(s) available for isoxazoles and hp 873
| Article | Year |
|---|---|
An assessment of iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2000 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Isoxazoles; Marketing; Piperidines; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Structure-Activity Relationship | 2008 |
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Patient Dropouts; Piperidines; Prospective Studies; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2008 |
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Prospective Studies; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Drug Labeling; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Sample Size; Schizophrenia; Treatment Outcome | 2009 |
Iloperidone: in schizophrenia.
Topics: Humans; Internationality; Isoxazoles; Multicenter Studies as Topic; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2009 |
Iloperidone: a new option for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Confidence Intervals; Humans; Isoxazoles; Kaplan-Meier Estimate; Longitudinal Studies; Piperidines; Schizophrenia | 2009 |
New atypical antipsychotics for schizophrenia: iloperidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2010 |
Iloperidone for schizophrenia.
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Drug Approval; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Drug Interactions; Evidence-Based Medicine; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Precision Medicine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
New antipsychotic drugs: how do their receptor-binding profiles compare?
Topics: Antipsychotic Agents; Brain; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Paliperidone Palmitate; Piperidines; Pyrimidines; Receptors, Neurotransmitter | 2010 |
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Topics: Adult; Animals; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Half-Life; Humans; Isoxazoles; Piperidines; Receptors, Adrenergic, alpha-1; Schizophrenia | 2010 |
Iloperidone: A new drug for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Humans; Isoxazoles; Piperidines; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2011 |
Iloperidone for the management of adults with schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2011 |
Iloperidone: a clinical overview.
Topics: Antipsychotic Agents; Electrocardiography; Heart Rate; Humans; Isoxazoles; Long QT Syndrome; Piperidines; Schizophrenia; Treatment Outcome; Weight Gain | 2011 |
Iloperidone for the treatment of schizophrenia: an updated clinical review.
Topics: Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Hospitalization; Humans; Isoxazoles; Piperidines; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2012 |
ACS chemical neuroscience molecule spotlight on Fanapt.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Device Approval; Dopamine Agonists; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; United States; United States Food and Drug Administration | 2010 |
Iloperidone, asenapine and lurasidone: a primer on their current status.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lipid Metabolism; Lurasidone Hydrochloride; Paliperidone Palmitate; Piperidines; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2013 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
Safety profile of iloperidone in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2014 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Drug Design; Drug Monitoring; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
An update on the efficacy and safety of iloperidone as a schizophrenia therapy.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Weight Gain | 2020 |
17 trial(s) available for isoxazoles and hp 873
| Article | Year |
|---|---|
Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic.
Topics: Adolescent; Adult; Antipsychotic Agents; Biological Availability; Drug Tolerance; Food-Drug Interactions; Half-Life; Humans; Intestinal Absorption; Isoxazoles; Male; Metabolic Clearance Rate; Piperidines; Time Factors | 1995 |
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
Topics: Adult; Antipsychotic Agents; Ciliary Neurotrophic Factor; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Placebos; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Racial Groups; Schizophrenia; Schizophrenic Psychology | 2008 |
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Thiazoles; Treatment Outcome | 2008 |
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Genome-Wide Association Study; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Isoxazoles; Male; Middle Aged; Nerve Tissue Proteins; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Pseudogenes; Receptors, AMPA; Schizophrenia; Tenascin; Thiazoles; Transcription Factors; Young Adult | 2009 |
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Carrier Proteins; CELF Proteins; Cytoskeletal Proteins; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Isoxazoles; Linear Models; Linkage Disequilibrium; Long QT Syndrome; Male; Middle Aged; Neuregulins; Organic Anion Transporters; Pharmacogenetics; Phosphoproteins; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Piperidines; Polymorphism, Single Nucleotide; RNA-Binding Proteins; Schizophrenia; Thiazoles; Young Adult | 2009 |
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Double-Blind Method; Female; Genetic Markers; Genotype; Humans; Isoxazoles; Likelihood Functions; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Probability; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
Topics: Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Gene Frequency; Genotype; Humans; Isoxazoles; Male; Piperazines; Piperidines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2C; Schizophrenia; Thiazoles; Weight Gain | 2010 |
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Mood Disorders; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult | 2011 |
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Topics: Adult; Antipsychotic Agents; Apoptosis Regulatory Proteins; Benzodiazepines; Biomarkers, Pharmacological; Black or African American; Drug Resistance; Genotype; Humans; Isoxazoles; Membrane Proteins; Membrane Transport Proteins; Olanzapine; Piperidines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, AMPA; Risperidone; Schizophrenia; White People | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dibenzothiazepines; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Electrocardiography; Enzyme Inhibitors; Female; Genotype; Heart Rate; Humans; Isoxazoles; Ketoconazole; Linear Models; Long QT Syndrome; Male; Middle Aged; Paroxetine; Pharmacogenetics; Phenotype; Piperazines; Piperidines; Quetiapine Fumarate; Thiazoles; United States; Young Adult | 2013 |
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Humans; India; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; United States; Young Adult | 2013 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Recurrence; Schizophrenia; Secondary Prevention; Treatment Outcome | 2016 |
An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder.
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Bipolar Disorder; Female; Humans; Isoxazoles; Male; Piperidines; Treatment Outcome; Urinary Incontinence; Urinary Incontinence, Urge; Young Adult | 2017 |
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Eating; Energy Metabolism; Female; Glucose Tolerance Test; Healthy Volunteers; Humans; Insulin; Insulin Resistance; Isoxazoles; Lipids; Male; Obesity; Olanzapine; Piperidines; Weight Gain; Young Adult | 2018 |
53 other study(ies) available for isoxazoles and hp 873
| Article | Year |
|---|---|
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozapine; Dopamine Antagonists; Haloperidol; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Risperidone; Saimiri; Serotonin Antagonists | 1995 |
Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoxazoles; Mass Spectrometry; Piperidines; Reproducibility of Results | 1995 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Catalepsy; Chlorpromazine; Clozapine; Diazepam; Haloperidol; Isoxazoles; Male; Mice; Mice, Inbred Strains; Piperidines; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Social Behavior | 1993 |
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Dopamine Antagonists; In Vitro Techniques; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 1995 |
Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone.
Topics: Animals; Antipsychotic Agents; Bile; Biotransformation; Chromatography, Liquid; Dogs; Humans; In Vitro Techniques; Isoxazoles; Liver; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Piperidines; Rats; Rats, Wistar; Spectrophotometry, Infrared; Subcellular Fractions | 1995 |
Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Autoradiography; Brain; Dihydroxyphenylalanine; Dopamine Antagonists; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Serotonin Antagonists | 1996 |
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |
Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Isoxazoles; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Piperidines | 1998 |
Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
Topics: Animals; Antipsychotic Agents; Cattle; CHO Cells; Clozapine; Cricetinae; Dopamine Agonists; Guinea Pigs; Humans; In Vitro Techniques; Isoxazoles; Male; Membranes; Piperidines; Rats; Rats, Wistar; Receptors, Adrenergic; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Dopamine; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Serotonin; Serotonin Receptor Agonists | 2001 |
Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone.
Topics: 3T3 Cells; Animals; Antipsychotic Agents; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Humans; Isoxazoles; Male; Mice; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin | 2002 |
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Butyrophenones; Clozapine; Dibenzothiazepines; Dopamine; Haloperidol; Isoxazoles; Male; Microdialysis; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1 | 2002 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Antipsychotic Agents; Brain Chemistry; Clozapine; Dose-Response Relationship, Drug; Electric Stimulation; Excitatory Amino Acid Antagonists; Haloperidol; In Vitro Techniques; Isoxazoles; Magnesium; Male; Neuronal Plasticity; Patch-Clamp Techniques; Piperidines; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission; Time Factors | 2003 |
Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.
Topics: Animals; Antipsychotic Agents; Cell Line; Cricetinae; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piperidines; Receptors, Biogenic Amine; Transfection | 2003 |
Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Choice Behavior; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Isoxazoles; Male; Memory, Short-Term; Muscarinic Antagonists; Nose; Piperidines; Rats; Reaction Time; Scopolamine; Time Factors | 2003 |
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
Topics: Acoustic Stimulation; Adrenergic alpha-Agonists; Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Excitatory Amino Acid Antagonists; Gait Disorders, Neurologic; Imidazoles; Isoxazoles; Male; Neural Inhibition; Phencyclidine; Piperidines; Rats; Rats, Sprague-Dawley; Reflex, Startle | 2006 |
New advances in the treatment of schizophrenia. Introduction.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2008 |
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Endpoint Determination; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Iloperidone (Fanapt)--another second-generation antipsychotic.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Atypical antipsychotics: the two new arrivals.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Piperidines; Safety; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Iloperidone: Does it have a meaningful place in therapy?
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Humans; Isoxazoles; Piperidines; Schizophrenia | 2011 |
Update on newer antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Pregnancy; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Biological perspectives: update on newer antipsychotic drugs: are they evidence based?
Topics: Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Dibenzocycloheptenes; Evidence-Based Medicine; Heterocyclic Compounds, 4 or More Rings; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoindoles; Isoxazoles; Lactones; Lurasidone Hydrochloride; Piperidines; Psychotic Disorders; Pyridines; Serotonin Receptor Agonists; Sulfones; Thiazoles | 2011 |
Scaffold hopping for identification of novel D(2) antagonist based on 3D pharmacophore modelling of illoperidone analogs.
Topics: Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Isoxazoles; Models, Molecular; Molecular Conformation; Piperidines; Quantitative Structure-Activity Relationship | 2012 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |
Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.
Topics: Action Potentials; Animals; Antipsychotic Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography, Ambulatory; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart Conduction System; HEK293 Cells; Humans; Isoxazoles; Male; Patch-Clamp Techniques; Perfusion; Piperidines; Potassium Channel Blockers; Risk Assessment; Telemetry; Time Factors; Transfection | 2012 |
Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes.
Topics: Adult; Angioedema; Antipsychotic Agents; Drug Hypersensitivity; Haloperidol; Humans; Isoxazoles; Male; Piperidines | 2012 |
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Dibenzocycloheptenes; Fasting; Female; Glucose Clamp Technique; Glucose Tolerance Test; Heterocyclic Compounds, 4 or More Rings; Hyperinsulinism; Insulin Resistance; Isoxazoles; Metabolism; Olanzapine; Piperidines; Rats; Rats, Sprague-Dawley | 2013 |
Iloperidone-induced retrograde ejaculation.
Topics: Antipsychotic Agents; Capgras Syndrome; Ejaculation; Humans; Isoxazoles; Male; Piperidines; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult | 2013 |
Stable-isotope dilution LC-MS/MS assay for determination of iloperidone and its two major metabolites, P 88 and P 95, in human plasma: application to a bioequivalence study.
Topics: Antipsychotic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Deuterium; Half-Life; Humans; Isotope Labeling; Isoxazoles; Piperidines; Solid Phase Extraction; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Antipsychotic Agents; Chromatography, Liquid; Dopamine D2 Receptor Antagonists; Humans; Isoxazoles; Liquid-Liquid Extraction; Male; Piperidines; Sensitivity and Specificity; Serotonin 5-HT2 Receptor Antagonists; Tandem Mass Spectrometry | 2013 |
Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect.
Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Depressive Disorder, Major; Dizziness; Drug Interactions; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Isoxazoles; Male; Paroxetine; Pharmacogenetics; Piperidines; Precision Medicine | 2013 |
Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Humans; Isoxazoles; Piperidines; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Isoxazoles; Lipids; Male; Nanoparticles; Particle Size; Piperidines; Rats; Rats, Wistar; Solubility; Surface-Active Agents | 2015 |
Psychotropic exposures in pediatric patients: Symptomatic iloperidone and vilazodone ingestions.
Topics: Age Factors; Benzofurans; Child, Preschool; Female; Humans; Indoles; Infant; Isoxazoles; Male; Piperazines; Piperidines; Poisoning; Psychotropic Drugs; Risk Factors; Time Factors; Vilazodone Hydrochloride | 2015 |
Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.
Topics: Antipsychotic Agents; Computer Simulation; Genotype; Humans; Isoxazoles; Models, Biological; Molecular Targeted Therapy; Neurobiology; Pharmacogenetics; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2015 |
Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster.
Topics: Adrenergic Uptake Inhibitors; Alcohol Drinking; Animals; Antipsychotic Agents; Clozapine; Cricetinae; Desipramine; Isoxazoles; Male; Mesocricetus; Piperidines | 2016 |
Flow Synthesis in Hot Water: Synthesis of the Atypical Antipsychotic Iloperidone.
Topics: Antipsychotic Agents; Isoxazoles; Piperidines; Temperature; Water | 2016 |
Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
Topics: Antipsychotic Agents; Child, Preschool; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Infant; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Poison Control Centers; Retrospective Studies; United States | 2018 |
Supported liquid extraction and LC-MS-MS determination of iloperidone and olanzapine in rat plasma: Application to a pharmacokinetic study.
Topics: Animals; Chromatography, Liquid; Isoxazoles; Limit of Detection; Linear Models; Male; Olanzapine; Piperidines; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Topics: Adverse Drug Reaction Reporting Systems; Akathisia, Drug-Induced; Antipsychotic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Piperidines; United States; United States Food and Drug Administration | 2019 |
Transdermal lipid vesicular delivery of iloperidone: Formulation, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Antipsychotic Agents; Biological Availability; Cholesterol; Dermis; Drug Compounding; Ear; Ethylene Glycols; Gels; Isoxazoles; Liposomes; Particle Size; Permeability; Piperidines; Rats; Rats, Wistar; Skin Absorption; Swine | 2019 |
Repurposing of Iloperidone: Antihypertensive and ocular hypotensive activity in animals.
Topics: Animals; Antihypertensive Agents; Antipsychotic Agents; Blood Pressure; Desoxycorticosterone Acetate; Drug Repositioning; Female; Hypertension; Intraocular Pressure; Isoxazoles; Male; Molecular Docking Simulation; Piperidines; Rats, Wistar; Receptors, Adrenergic, alpha-1; Rotarod Performance Test | 2020 |
Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Chemistry, Pharmaceutical; Dizocilpine Maleate; Drug Carriers; Emulsions; Excipients; Humans; Isoxazoles; Locomotion; Male; Models, Animal; Particle Size; Piperidines; Rats; Schizophrenia; Solubility; Surface-Active Agents; Suspensions; Tablets | 2020 |
The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
Topics: Animals; Antipsychotic Agents; Baculoviridae; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Humans; Insecta; Isoxazoles; Lurasidone Hydrochloride; Microsomes, Liver; Piperidines | 2020 |
Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Topics: Antipsychotic Agents; Cell Survival; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dibenzocycloheptenes; Drug Interactions; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; L-Lactate Dehydrogenase; Lurasidone Hydrochloride; Piperidines; RNA, Messenger | 2020 |
Pharmacokinetic and pharmacodynamic studies of iloperidone-loaded lipid nanoemulsions via oral route of administration.
Topics: Administration, Oral; Animals; Biological Availability; Isoxazoles; Lipids; Nanoparticles; Particle Size; Piperidines; Rats | 2021 |
Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Cannabidiol; Cell Culture Techniques; Cerebral Cortex; Disease Models, Animal; Female; Isoxazoles; Male; Neurons; Piperidines; Rats; Rats, Sprague-Dawley; Schizophrenia; Sex Characteristics | 2021 |
The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms.
Topics: Animals; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Gene Expression; Isoxazoles; Liver; Male; Microsomes, Liver; Piperidines; Rats; Rats, Wistar; Schizophrenia | 2021 |
Effects of iloperidone on hERG 1A/3.1 heterotetrameric channels.
Topics: Biotinylation; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Isoxazoles; Piperidines; Potassium Channel Blockers | 2021 |
Pharmacological agents selectively acting on the channel moieties of TRPM6 and TRPM7.
Topics: Animals; Humans; Isoxazoles; Magnesium; Mice; Piperidines; Protein Serine-Threonine Kinases; Purine Nucleosides; Transient Receptor Potential Channels; TRPM Cation Channels | 2022 |
Optimization and characterization of self-nanoemulsifying drug delivery system of iloperidone using box-behnken design and desirability function.
Topics: Administration, Oral; Drug Delivery Systems; Emulsions; Isoxazoles; Nanoparticles; Particle Size; Solubility; Surface-Active Agents | 2023 |